Apple reported its Q1 2025 earnings after the bell Thursday, beating on expectations, but falling short on iPhone sales.
Oppenheimer initiated coverage on Alumis Inc (NASDAQ:ALMS) with an Outperform rating and a price target of $32.00. The firm's analysts highlighted the biopharmaceutical company's focus on developing ...
PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes ...
In a report released yesterday, Irene Nattel from RBC Capital reiterated a Buy rating on SAP AG (SAP – Research Report), with a price target of ...
AGCO (NYSE:AGCO – Get Free Report) had its price target raised by Oppenheimer from $108.00 to $109.00 in a research report ...